For the second time this year, X4 Pharmaceuticals is enacting a “strategic restructuring” initiative, in which it will let go of half of its employees in a bid to “sharpen operational focus and align resources” with its long-term strategy, These most recent staffing cuts are expected to affect some 50 employees. The strategic push will cost the company $3.3 million in one-time expenses for severance and other termination-related payments. Annualized savings are expected to hit $13 million, according to the SEC filing. X4 is also trimming its masthead. The biotech’s Board has terminated Chief Operating Officer Mary DiBiase, Chief Commercial Officer Mark Baldry and Chief Legal and Compliance Officer Natasha Thoren, all effective Sept. 15. A day later, Chief Medical Officer Christophe Arbet-Engels stepped down from his post.
All entries for: X4 Pharmaceuticals
X4 Pharmaceuticals
Neutral Outlook
Boston, MA
51-200 employees
“Multiple recent executive actions have signaled the federal government’s increasing focus on lowering prescription drug prices, adding to the uncertainty surrounding future drug pricing and reimbursement frameworks. For example:
•On May 12, 2025, President Trump signed the executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing,” which directs the Secretary of Health and Human Services (HHS) to identify and communicate most-favored-nation price targets for prescription drugs and to propose a rulemaking plan to impose such pricing if “significant progress” is not made. The order also directs the federal government to explore regulatory pathways that would facilitate direct-to-patient sales for manufacturers that meet these price targets. Additionally, it signals potential further action against manufacturers that fail to offer most-favored-nation pricing, including evaluating whether to modify or rescind marketing approvals or allow individual drug importation waivers.”